Brief: GH Research Announces Grant of European Patent Covering All Mebufotenin (5-MeO-DMT) And Mebufotenin Salt Products For Use in the Treatment of Major Depressive Disorder and Treatment-Resistant Depression
18/01/2024 23:18
Jan 18 (Reuters) - GH Research PLC GHRS.O :
* GH RESEARCH ANNOUNCES GRANT OF EUROPEAN PATENT COVERING
ALL
MEBUFOTENIN (5-MEO-DMT) AND MEBUFOTENIN SALT PRODUCTS FOR USE IN
THE TREATMENT OF MAJOR DEPRESSIVE DISORDER AND
TREATMENT-RESISTANT DEPRESSION
* GH RESEARCH PLC: NEWLY GRANTED PATENT, EP3927337, WILL
HAVE AN
EFFECTIVE DATE OF FEBRUARY 14, 2024, AND AN EXPIRY DATE OF NO
EARLIER THAN 2040
Source text for Eikon: ID:nGNXhjQDV
Further company coverage: GHRS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on GH Research
See all newsCorrected: UPDATE 2-Experts urge FDA to set clear safety and access standards for psychedelic drugs (September 14)
FDA to hold public hearing on psychedelic drugs as Trump-driven push gathers pace
Ireland's GH Research Q2 net loss widens on higher R&D costs
AtaiBeckley surges after report Lilly poised to buy psychedelic drug developer
Street View: Psychedelic sector gains after report Lilly nears AtaiBeckley acquisition